Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aevi Genomic Medicine, Inc. (NASDAQ: GNMX).

Full DD Report for GNMX

You must become a subscriber to view this report.


Recent News from (NASDAQ: GNMX)

Aevi Genomic reports Q3 results
Aevi Genomic (NASDAQ: GNMX ): Q3 GAAP EPS of -$0.12. More news on: Aevi Genomic Medicine, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 01 2018 08:07
Aevi Genomic Medicine Reports Third Quarter 2018 Financial Results and Provides Business Update
PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September 30 , 2018 and provided an overview of the Company's recent corporate progress. Thir...
Source: PR Newswire
Date: November, 01 2018 07:30
New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), Neos Therapeutics, Inc. (NASDAQ:NEOS)...
Source: GlobeNewswire
Date: October, 16 2018 07:35
Aevi Genomic Medicine advancing mid-stage study of AEVI-001 in ADHD; shares up 2%
Thinly traded nano cap Aevi Genomic Medicine ( GNMX +1.9% ) is up on below-average volume following its announcement that Part B of its Phase 2 ASCEND study evaluating AEVI-001 in pediatric and adolescent patients with attention deficit hyperactivity disorder (ADHD) is now fully enrolled...
Source: SeekingAlpha
Date: October, 15 2018 10:29
Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial
PHILADELPHIA , Oct. 15, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial.  The ASCEND trial is a genomically-guided study in pediatric and adolescent...
Source: PR Newswire
Date: October, 15 2018 08:00
Aevi Genomic Medicine (GNMX) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 14:55
FDA rejects Sunovion's dasotraline for ADHD
Privately-held Sunovion Pharmaceuticals has received a CRL from the FDA in response to its marketing application seeking approval for dasotraline, a dual-acting dopamine and norepinephrine reuptake inhibitor, for the treatment of attention deficit hyperactivity disorder (ADHD). More ne...
Source: SeekingAlpha
Date: August, 31 2018 09:47
Aevi Genomic Medicine to Present at the H.C. Wainwright 20th Annual Global Investment Conference
PHILADELPHIA , Aug. 29, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5,...
Source: PR Newswire
Date: August, 29 2018 08:00
Daily Insider Ratings Round Up 8/17/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: August, 21 2018 12:58
Aevi Genomic Medicine Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial
PHILADELPHIA , Aug. 21, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced the sale of 5.1 million shares of its common stock for aggregate proceeds of $4.9 million, before expenses. The sales were through the Company's existing ATM progra...
Source: PR Newswire
Date: August, 21 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-081.161.111.161.1092,760
2018-05-171.521.621.631.5273,638

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1210,01034,75128.8049Cover
2018-12-115,09047,66510.6787Cover
2018-12-1045,165121,11637.2907Short
2018-12-07123,821292,33742.3556Short
2018-12-0616,78620,08883.5623Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GNMX.


About Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)

Logo for Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)

Not available

 

Contact Information

 

 

Current Management

  • John Leaman / CFO
  • Barbara G. Duncan /

Current Share Structure

  • Market Cap: $88,412,525 - 05/11/2018
  • Issue and Outstanding: 59,337,265 - 03/09/2018

 


Recent Filings from (NASDAQ: GNMX)

Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: May, 16 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: May, 16 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 15 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 15 2018
Information for Proxy Statement under Rule 14a-101
Filing Type: DEFR14AFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018

 

 


Daily Technical Chart for (NASDAQ: GNMX)

Daily Technical Chart for (NASDAQ: GNMX)


Stay tuned for daily updates and more on (NASDAQ: GNMX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GNMX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GNMX and does not buy, sell, or trade any shares of GNMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/